Trials / Completed
CompletedNCT04136873
A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia
A Phase 1B Trial To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of CVL-231 in Subjects With Schizophrenia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 130 (actual)
- Sponsor
- Cerevel Therapeutics, LLC · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CVL-231 following multiple-dose oral administration in subjects with schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CVL-231 | CVL-231 |
| DRUG | Matching Placebo | Placebo matching CVL-231 |
Timeline
- Start date
- 2019-10-15
- Primary completion
- 2021-05-07
- Completion
- 2021-06-03
- First posted
- 2019-10-23
- Last updated
- 2021-07-02
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04136873. Inclusion in this directory is not an endorsement.